Welcome to the Hope Bio Blog

– FOR IMMEDIATE RELEASE – CONTACT: Jan Shultis | Phone: (281) 725-1272 | Email: jan@hope.bio | Sugar Land, Texas Sugar Land, Texas 28 April 2021: In the months to come, Houston area biopharmaceutical company Hope Biosciences will send more than 24 billion stem cells to the fight against Parkinson’s Disease. Hope Biosciences cultures pure mesenchymal stem cells, a type of stem cell found in adult fat, to develop cell-based therapeutics for a variety of indications. This week

Mesenchymal Stem Cells for Treatment of Hospitalized COVID-19 Patients Monday, April 20, Houston - Hope Biosciences announces FDA approval on their third clinical trial for COVID-19. This study will be conducted in collaboration with Advanced Diagnostics Healthcare (ADH) at River Oaks Hospital and Clinics. The hospital has an entire floor dedicated to treating COVID-19 patients, with staff specifically trained to care for these patients. The goal of this collaboration is to

Allogeneic Mesenchymal Stem Cells for Frontline Workers to Provide Immune Support Against COVID-19 Hope Biosciences, a clinical stage biotechnology company focused on developing cell-based therapeutics for acute and chronic disease, today announced that FDA has approved a Phase II clinical trial evaluating the safety and efficacy of Hope Biosciences’ allogeneic, adipose-derived mesenchymal stem cells (HB-adMSCs) to provide immune support against COVID-19. During this pandemic